Objective: To examine the influence of systemic nitric oxide (NO) synthesis on blood pressure in patients with chronic renal failure undergoing haemodialysis, since nitric oxides are susceptible to renal excretion or are dialysed, a different indicator that is unaffected by renal function, such as the level of exhaled NO was evaluated. We examined the levels of the endogenous NO before and after a haemodialysis session. Design and methods: We evaluated the serum concentrations of nitrite/nitrate and the rate of nitric oxide release into exhaled air in 10 patients with hypertension who were receiving maintenance haemodialysis. Results: The serum concentrations of nitrite/nitrate before haemodialysis were significantly higher than those in 10 normal controls (183 ؎ 151 M vs 42 ؎ 17 M, P Ͻ 0.05). These levels decreased signifi-
Introduction
Endogenous nitric oxide (NO) is synthesised from l-arginine with a coproduct of l-citrulline by several isoenzymes of NO synthase (NOS). 1, 2 It is now widely accepted that l-arginine-derived NO plays a significant role in the regulation of systemic haemodynamics by means of a relaxing the microvasculature. A new model of hypertension has been developed by chronic inhibition of NO synthesis using the active inhibitor NG-nitro-l-arginine methyl ester. 3, 4 Chronic NO blockade causes dosedependent increases in systolic blood pressure. Renal failure is often accompanied by hypertension, and interestingly, patients with renal failure have been shown to possess high levels of guanidinosubstituted analogues of l-arginine compounds that inhibit NO synthesis. [5] [6] [7] Since guanidino compounds can be removed by dialysis, 8 their serum levels should decrease after haemodialysis in uraemic patients. In contrast to the hypertensionrelated effects of NO, overproduction of NO due to cantly by the end of haemodialysis (42 ؎ 26 M). Because the amount of nitric oxide in the deepest expirate correlated well with the duration of exhalation, we were able to derive the rate of release of NO. The rate of NO release was 0.034 ؎ 0.012 nmol/sec before haemodialysis, similar to that in normal controls (0.031 ؎ 0.013 nmol/sec). The rate was significantly reduced after dialysis (0.023 ؎ 0.010 nmol/sec) (P Ͻ 0.05). The mean pre-dialysis mean blood pressure (109 ؎ 11 mm Hg) and the post-dialysis blood pressure (106 ؎ 9 mm Hg) were the same. Conclusions: These data indicate that NO production does not appear to have a critical role in control of arterial blood pressure across haemodialysis in patients with chronic renal failure.
induction of NOS by cytokines activated by dialysis membranes or lipopolysaccharide contamination has been proposed as a possible cause of haemodialysis-related hypotension. [9] [10] [11] NO is highly unstable with a plasma half-life of only a few seconds, 12 so that its direct measurement is difficult, particularly in vivo. The amount of endogenously produced NO is determined by two methods; one measures the serum levels of nitrite/nitrate, products of NO metabolism, and the other measures endogenous NO in expired air. Nitrite/nitrate is excreted principally in urine, and these ionised molecules are easily dialysed. Therefore it is inappropriate to apply the serum level as an indicator of endogenously produced NO in patients with renal failure who are undergoing maintenance haemodialysis. Although the actual cellular source of exhalated NO is not known, it has been proposed that all NOS isoforms in the respiratory system contribute to NO release. 13, 14 Also, it is unlikely that the NO in expired air is not directly affected by renal function.
To investigate whether systemic NO synthesis influences blood pressure in chronic renal failure patients receiving maintenance haemodialysis, we evaluated the endogenous production of NO before and after a single haemodialysis session by measuring the rate of NO release into expired air and by measuring the serum levels of nitrite/nitrate.
Materials and methods

Patient characteristics and clinical protocol
Ten Japanese patients with end-stage renal failure who were receiving maintenance haemodialysis were selected for study (Table 1) . Their mean age was 42 ± 12 years; their mean duration of haemodialysis was 7.8 ± 4.6 years. All patients had hypertension and were receiving antihypertensive agents. None had symptoms of respiratory disease. This study was approved by our institutional committee on human research. Informed consent for participation was obtained from each subject.
All patients (seven men and three women) had dialysis consecutively with each of three specific dialysers in the same week. Haemodialysis procedures were performed in conjunction with a volumetric control device (TR 221; Toray, Tokyo, Japan). The cellulose-based membrane (Cuprophane) had a surface area of 1.5 square meters (m 2 ) with a pore size from 15 to 35 Å. The polysulfone membrane had a surface area of 1.8 m 2 with a pore size from 60 to 80 Å. Blood flow rates were 300 mL/min for Cuprophane and 400 mL/min for Polysulfone. For both membranes the dialysate flow rates were 500 mL/min and the dialysis time were 4 h per session. The dialysate used contained sodium (140 mmol/L), potassium (2.0 mmol/L), calcium (1.5 mmol/L) and bicarbonate (17.5 mmol/L). All patients received a bolus dose of heparin, 1300 U, at the start of dialysis, followed by 750 U/h thereafter.
The concentrations of nitrite and nitrate in the dialysate were below the limits of detection. The volume of urine excreted was less than 250 mL per day in all patients. Venous blood was collected in sterile plastic tubes. Samples of exhaled air and of venous blood samples were collected before and at the end of one routine dialysis session. Ten healthy Japanese subjects, age-and sex-matched volunteers (seven men and three women, ages 23 to 55 years, mean 41 ± 11 years), served as controls for each of the parameters measured.
The collection of samples of exhaled air, analysis of NO gas
Samples of exhaled air, the analysis of NO gas, and determination of the rate of NO release were perfor- Chronic nephritis Cuprophane C A = angiotensin-converting enzyme inhibitor; B = ␤-receptor blocker; C = calcium channel blocker.
med as described previously with minor modifications for determining the release rate of NO. 15 In brief, the patients were allowed to sit and breathe normally for 10 min before the samples were collected. With a nose clip in place, air inspired through the mouth was exhaled through the mouth into a 6-liter bag of polyvinylfluoride film (Tedlar bag, Iuchi, Tokyo, Japan). A Teflon column (15 Å to 50 mm) was inserted between the mouthpiece and the Tedlar bag. The column was packed with 6.7 g silica gel (particle size 1.7 to 4.0 mm, Kanto Chemical, Tokyo, Japan). This column was used to dry the exhaled air sufficiently to prevent condensation of vapour on the walls of the Tedlar bag.
NO gas analysis and determination for release rate
A chemiluminescence analyser (Model GLN-32; Denki-Kagaku-Keiki, Tokyo, Japan) was used to measure the concentration of NO. The flow rate for sampling was 800 mL/min. The detection limit for NO was 0.2 parts per billion (ppb) and the coefficient of variation was 2% at 20 ppb of NO.
After a full inspiratory effort, the subject was instructed to exhale air at six flow rates that were determined arbitrarily by each subject. These flow rates ranged from very fast to very slow with the air volume of these six efforts corresponding to the individuals vital capacity. The six samples were collected in separate bags. The time from the start to the end of each sampling was measured with a stopwatch. Sample volumes were determined on a chart recorder (Model 056 Recorder; Hitachi, Tokyo, Japan). The amount of NO (nmol) in the sample of exhaled air was calculated as b × V × 24.5
; where b (ppb) is the concentration of the exhaled air sample, V (L) is the sample volume, and 24.5 (L) corresponds to the volume of 1 mol dry gas at 25°C and 760 mm Hg. Since in a preliminary study the amount of NO in one exhalation correlated positively with the duration of exhalation, a simple least-square linear regression model was applied and the slope was regarded as the NO release rate. The release rate was constant (0.035 ± 0.004 nmol/sec) in one control subject who repeated the protocol 10 times over a 2-week period.
Determination of serum levels of nitrite/nitrate (NOx) and amino acid
Samples of venous blood were centrifuged at 500 g for 10 min at 4°C. The resulting sera were stored at −70°C until assayed. For NOx measurements, 0.125 mL of thawed serum was added to 0.5 ml of 75 mM ZnSO 4 solution, to which 0.625 mL of 55 mM NaOH was added. The final pH was maintained between 7.0 and 7.5. Treated samples were mixed by vortex, allowed to stand for 10 min and then centrifuged at 5000 g for 10 min. The resulting supernatant was applied to a copperised cadmium reduction column to reduce nitrate to nitrite, and subsequently was allowed to react with the Griess reagent by using an auto-analyser (TCI-NOX 1000; Tokyo Kasei Kogyo, Tokyo, Japan). The absorbance of the reaction mixture at 540 nm was quantitated by spectrophotometry. The limit of nitrite detection was 0.2 M.
The concentration of serum amino acids was determined by using an amino acid auto-analyser (Model L-8500; Hitachi) fitted with an ion-exchange column. The minimum limit for the detection of aspartate was 10 pmol.
Determination of plasma levels of cyclic 3Ј,5Ј-guanosine monophosphate (cGMP) Blood samples were drawn into the tubes containing anticoagulant. A commercial kit (Amersham, Tokyo, Japan) was used to measure plasma cGMP levels after extraction by ethanol.
Statistical analysis
Data are expressed as mean ± s.d. The paired Student's t-test was used to analyse the differences between data sets before and after haemodialysis sessions. The unpaired two-tailed Student's t-test was used to analyse the differences between the results from normal controls and patients with renal failure. A P value Ͻ0.05 was accepted as statistically significant.
Results
Change in serum levels of blood urea nitrogen (BUN), creatinine, and total protein
Serum levels of blood urea nitrogen (BUN) and creatinine decreased significantly following haemodialysis (BUN, from 70 ± 17 mg/dL to 27 ± 5 mg/dl, P Ͻ 0.0001; creatinine, from 13.4 ± 3.1 mg/dL to 5.8 ± 1.3 mg/dL, P Ͻ 0.0001). Serum total protein levels increased significantly from 6.5 ± 0.4 g/dL to 7.3 ± 0.6 g/dL following haemodialysis (P Ͻ 0.01).
Rate of NO release in the airway
We observed a significant positive correlation between the duration of exhalation and the amount of NO exhaled (Figure 1 ). The slope (nmol/sec) of Figure 1 Relationship between the amount of NO exhaled and the duration of exhalation in uraemic patients before (᭺), and after (b) a haemodialysis session. Single regression analysis using the least-squares method revealed a significant correlation between these variables (P Ͻ 0.045 for all subjects at all points). the linear regression equation relating to the duration of exhalation to the amount of NO released was defined as the rate of NO release in the airway. During haemodialysis, the NO release rate was apparently reduced in eight patients and slightly elevated in two patients (Figure 2 ). The rate of NO release was reduced significantly from a pre-dialysis level of 0.034 ± 0.012 nmol/sec to a post-dialysis level of 0.023 ± 0.010 nmol/sec (P Ͻ 0.05). The rate of NO release did not differ between the control subjects (0.031 ± 0.013 nmol/sec) and the patients with renal failure before haemodialysis. The rate of NO release was examined at the beginning of the next haemodialysis session in five patients. The concentration of NO in room air was measured at 1.1 ± 0.6 ppb just before the study was performed.
Change in serum levels of nitrite/nitrate
During haemodialysis, the serum concentrations of nitrite/nitrate decreased in all patients from 183 ± 151 M to 42 ± 26 M (P Ͻ 0.05) (Figure 3) . The pre-dialysis concentration of nitrite/nitrate was significantly higher in the renal failure patients relative to controls (P Ͻ 0.05). After dialysis, this value dropped to control levels (42 ± 17 M). The serum nitrite/nitrate after haemodialysis was reduced to a greater extent than either the BUN or creatinine levels (nitrite/nitrate, 77 ± 11%; BUN, 61 ± 4%; creatinine, 57 ± 4%).
Change in blood pressure by haemodialysis
No patient experienced hypotension, ie, a decline in mean blood pressure Ͼ20 mm Hg during haemodialysis. The mean blood pressure was 109 ± 11 mm Hg pre-dialysis and 106 ± 9 mm Hg post-dialysis. The change in mean blood pressure between these two points was 3 ± 10 mm Hg (range −18 to +17 mm Hg). The mean blood pressure on a nondialysis day over the time matched 4 h interval in the same patients was 107 ± 10 mm Hg and 107 ± 11 mm Hg, respectively. The value in these two points did not change. There was no correlation between the change in the mean blood pressure and the alteration in the rate of NO release (Figure 4 ).
Change in serum amino acid levels
Haemodialysis reduced the serum level of arginine and citrulline in all patients (83.6 ± 24.9 nmol/ml to 59.9 ± 21.7 nmol/ml, P Ͻ 0.05, and 121.9 ± 31.5 nmol/ml to 58.6 ± 20.0 nmol/ml, P Ͻ 0.001, respectively) ( Figure 5 ). There was no correlation between the change in the serum levels of the amino acids and the alterations in the rates of NO release. The pre-dialysis concentration was significantly lower for serum arginine and higher for serum citrulline as compared to controls (111.7 ± 18.0 nmol/ml, P Ͻ 0.01; 38.5 ± 11.4 nmol/ml, P Ͻ 0.001).
Change in plasma levels of cGMP
All plasma cGMP levels remained below the detectable limit of the assay (Ͻ0.31 pmol/mL).
Discussion
The rate of NO release in exhaled air was reduced by haemodialysis. This decrease was accompanied by a drop in the serum levels of nitrite/nitrate in patients with renal failure receiving maintenance haemodialysis. The production of NO prior to haemodialysis in the renal failure patients resembled that of normal controls. However, the patients exhibited a higher initial level of serum nitrite/nitrate relative to the same controls. With the exception of one report documenting that five patients showed no change in the expired levels of NO 1 h after beginning haemodialysis, 16 this is the first study to analyse changes in expired NO in uraemic patients before and after dialysis.
Enhanced production of NO with up-regulated cytokines such as interleukin-1 and tumor necrosis factor-␣ has been proposed of as a mechanism of hypotension related to haemodialysis. 9, 17, 18 Yokokawa and colleagues have shown that NO production, detected as plasma levels of nitrite and nitrate, was increased in patients who had a hypotensive episode during haemodialysis (decrease in mean blood pressure Ͼ20 mm Hg) and was not increased in those who did not have a hypotensive episode. 19 Their results indicate that the increased production of NO is involved in the lowering of blood pressure during haemodialysis, and that the plasma levels of nitrite and nitrate are reliable markers for the in vivo production of NO. However, we did not observe a correlation between the decrease in serum levels of nitrite/nitrate and the alterations in blood pressure during haemodialysis.
Nitrite and nitrate are principally eliminated by the kidney, either directly or after conversion to urea. 20 Therefore an impairment of renal function may cause an increase in nitrite/nitrate. Our observation that the concentration of nitrite/nitrate was higher in the renal dialysis patients than in the normal subjects supports previous findings. 21 A single haemodialysis treatment was more efficient in lowering the serum level of nitrite/nitrate than it was lowering the serum urea nitrogen or creatinine. This indicates that circulating nitrite/nitrate is efficiently dialysed. These results suggest that the serum levels of the end-products of NO metabolism are not admissible markers for the in vivo production of NO, at least when accompanied by impaired renal function.
NO has been detected in the exhaled air of animals and humans. 22 A variety of cell types, including the pulmonary endothelium, are potential sources of NO in the lung. 13 Nevertheless, the level of NO during exhalation differs in various pathophysiologic conditions; for examples, it is increased in patients with asthma, 23, 24 bronchiectasis, 25 systemic lupus erythematosus, 26 and liver cirrhosis. 27, 28 NO levels were also found to increase with exercise, 29, 30 during the mid menstrual cycle in women, 31 and during pregnancy. 32 Conversely, NO was reduced with ethanol ingestion. 33 These findings suggest that the level of exhaled NO not only represents its regional production in the airway, but also its systemic activity in various physiologic or pathologic conditions. This implies that the amount of NO in expired air is a reliable indicator of its in vivo production, even in the presence of renal dysfunction.
Extensive attempts has been made to establish NO's role in experimental hypertension, however, results of these studies have been highly divergent. 34 In the present study, the in vivo production of NO was not decreased in patients with renal failure, and was reduced without a significant alternation of systemic blood pressure following a single session of haemodialysis. Since there were no alternation of blood pressure on a non-dialysis day, the effect of diurnal blood pressure may limit interpretation. It has been suggested that high levels of guanidinosubstituted analogues of l-arginine compounds and the reduced levels after haemodialysis 5 may reflect a decrease in systemic NO production. Thus, systemic NO production does not play a major role in regulating systemic blood pressure in patients with chronic renal failure receiving maintenance haemodialysis.
NO promotes the formation of cGMP, which causes vasodilation. 35 Yokokawa et al 19 demonstrated that plasma levels of cGMP decrease after haemodialysis. In our study, however, plasma cGMP levels were below the detectable limit. It is still uncertain that the vasopressor effect of nitric oxide is related to vascular cGMP.
The in vivo production of NO was not decreased in patients with renal failure, and was reduced without a significant alteration of systemic blood pressure following a single session of haemodialysis. The NO production does not seem to have a critical role in the regulation of systemic blood pressure during haemodialysis. Moreover, nitrite/nitrate levels in dialysate remain unmeasurable but it will be needed in future study.
